Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Gbathaton Feb 19, 2022 8:24pm
153 Views
Post# 34445615

RE:RE:class war

RE:RE:class warProbably because the bigger companies are not offering what PMN wants, yet.  Nobody bought out Acumen yet either, and look at their market cap- $240M USD.

PMN's market cap is only $45M USD right now... so we are looking at a potential 6-bagger even if we just get to where Acumen is currently, which is not too far ahead of us... maybe 1 year.

The Boston group is providing the necessary capital to get to PhI.  After we get great results with the biomarker and safety data, then the leverage in negotiations goes up immensely.

It has been a long haul in getting to PhI, certainly, but I'm holding through PhI.  If we spike to acumen levels at the PhI start, I'll get my original investment out and ride the remaining 85% or so zero risk freebee shares into the sunset.

Cheers.
<< Previous
Bullboard Posts
Next >>